Skip to NavigationSkip to content

Johnson & Johnson

J&J lines up its Global Head for Actelion

Published on: 22/05/17

The deal is not yet complete but the last steps are assumed to be a formality – at least Johnson & Johnson’s appointment of a new Global Head for Actelion seems to suggest so. Jane Griffiths will step into the new role once the deal is closed. Griffiths currently serves as Company Group Chairman at Janssen EMEA, a subsidiary of J&J.

FDA demands new warnings for J&J diabetes drug over amputation risk

Johnson & Johnson has found itself in deep water again over the potentially harmful effects of its products. This time it has found itself the target of FDA scrutiny, as the organisation is now requiring the company to add new precautionary labelling to its diabetes treatment Invokana (canagliflozin), warning users of the risk of foot and leg amputations associated with its use.

The extent of these amputations most commonly involves the severance of the toe and middle of the foot, but could extend to below or even above the knee.

J&J chalks up another defeat in $110 million talc-cancer case

Talc in its natural form

Johnson & Johnson has suffered another defeat in a lawsuit against its talcum powder product. The latest case stands as the fifth trial over the safety of the product, and resulted in the judge ordering the company to pay $110 million.

In this particular instance, the case related to a Virginia woman who had suggested that she had developed ovarian cancer through using talcum powder for 40 years. She was diagnosed in 2012 and the cancer has since been found to have spread to the liver.

J&J acquires Neuravi to bolster neuro business

Image: PRNewsfoto/Codman Neuro

Johnson & Johnson’s neurosurgery and neurovascular unit, Codman Neuro, has made the move to acquire Galway-based company, Neuravi. The exact pricing of the deal has not been released but is understood to be the largest for a venture-backed medtech in Europe since 2009, as reported by the Irish Times. This places the deal in hundreds of millions and represents a huge success for the company and its investors.

EMA green lights Actelion’s drug after patient deaths scare

The EMA has ruled that the five patient deaths that occurred in February of this year were not directly related to Actelion’s Uptravi and it was therefore cleared for use. The patient deaths happened in France and were in patients who were receiving Uptravi for treatment of pulmonary arterial hypertension.

Closure of Scottish J&J plant threatens 400 staff

Johnson & Johnson has announced its intention to shut down its surgical suture manufacturing facility in Livingston, Scotland which sees up to 400 jobs facing the axe.  

The move is part of the company’s wider plan to streamline operations through a global restructuring effort originally announced at the beginning of last year, which planned to cut around 3,000 from its medical devices unit.

J&J latest pharma firm to volunteer pricing data

Johnson & Johnson released its pricing data, as promised, in February and it has simply revealed that its average price increases have been below the 10% mark annually for the last five years. It follows a similar path trodden by MSD, known as Merck in North America, in the release of a brief table of price increases but levelled against the ‘Net Price Change’ that factors in rebates and reimbursements.

Pfizer’s Remicade biosimilar displays similar efficacy

Pfizer and Celltrion have announced new data for their Remicade biosimilar, Inflectra, that shows that the drug is comparable in safety and efficacy, in a recent Phase 3 trial treating Crohn’s disease. Remicade was worth sales of $5.76 billion to Johnson & Johnson in 2015.

The March 2017 issue of Pharmafocus is now live!

The latest edition of Pharmafocus is available to read online now! From breakthroughs in antibiotic resistance R&D to gene editing in precision medicine, its a packed issue.

Integra bids $1.045 billion for J&J’s neurosurgery business

Integra, a medical technology company, have announced that it has made a binding offer to acquire Johnson & Johnson’s Codman Neurosurgery business in an offer worth $1.045 billion in cash. The deal will bring Codman’s portfolio of devices focused upon advanced hydrocephalus, neuro-critical care and operative neurosurgery.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches